Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetRent ExpenseShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Alterity Therapeutics (ATHE) Receivables - Net (2017 - 2025)

Alterity Therapeutics has reported Receivables - Net over the past 3 years, most recently at $3.4 million for Q2 2019.

  • For Q2 2019, Receivables - Net rose 41.75% year-over-year to $3.4 million; the TTM value through Jun 2019 reached $3.4 million, up 41.75%, while the annual FY2019 figure was $3.4 million, 41.75% up from the prior year.
  • Receivables - Net for Q2 2019 was $3.4 million at Alterity Therapeutics, up from $2.4 million in the prior quarter.
  • Over five years, Receivables - Net peaked at $3.4 million in Q2 2019 and troughed at $2.3 million in Q2 2017.
  • A 3-year average of $2.7 million and a median of $2.4 million in 2018 define the central range for Receivables - Net.
  • Biggest five-year swings in Receivables - Net: rose 4.65% in 2018 and later surged 41.75% in 2019.
  • Year by year, Receivables - Net stood at $2.3 million in 2017, then rose by 4.65% to $2.4 million in 2018, then surged by 41.75% to $3.4 million in 2019.
  • Business Quant data shows Receivables - Net for ATHE at $3.4 million in Q2 2019, $2.4 million in Q2 2018, and $2.3 million in Q2 2017.